• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

终末期肾病中的尾加压素II:交感神经功能与心钠素的负相关因素

Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides.

作者信息

Mallamaci Francesca, Cutrupi Sebastiano, Pizzini Patrizia, Tripepi Giovanni, Zoccali Carmine

机构信息

CNR-IBIM, Institute of Biomedicine, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension & Division of Nephrology, Dialysis and Transplantation, Reggio Calabria - Italy.

出版信息

J Nephrol. 2005 Nov-Dec;18(6):727-32.

PMID:16358231
Abstract

BACKGROUND

Urotensin II (UTN) is a peptide highly conserved across species with disparate effects on the vascular system and it is currently unclear whether high plasma UTN levels play a vasculotoxic or a vasculoprotective role.

METHODS

In this study, we investigated the relationship between plasma UTN and sympathetic activity and cardiac natriuretic hormones in 191 hemodialysis (HD) patients without clinical evidence of heart failure.

RESULTS

Plasma UTN was significantly higher in patients with end-stage renal disease (ESRD) (median: 6.5 ng/mL) than in age matched healthy subjects (median: 3.1 ng/mL) (p<0.001). On univariate analysis, UTN was inversely related to heart rate (r=-0.24), dialysis treatment duration (r=-0.27), norepinephrine (r=-0.28), neuropeptide Y (NPY) (r=-0.66), brain natriuretic peptide (BNP) (r=-0.41) and atrial natriuretic peptide (ANP) (r=-0.28) (all p<0.008). Of note, in multiple regression analyses these associations maintained strength similar to that of the corresponding unadjusted correlation coefficients.

CONCLUSIONS

The inverse links between UTN and neuro-hormonal factors indicate that UTN down-regulation in the presence of high sympathetic activity and high BNP could be a counter-regulatory response aimed at mitigating cardiovascular (CV) damage or that UTN itself acts as a protective factor.

摘要

背景

尾加压素II(UTN)是一种在物种间高度保守的肽,对血管系统有不同影响,目前尚不清楚血浆中高浓度的UTN发挥的是血管毒性作用还是血管保护作用。

方法

在本研究中,我们调查了191例无心力衰竭临床证据的血液透析(HD)患者血浆UTN与交感神经活动及心脏利钠激素之间的关系。

结果

终末期肾病(ESRD)患者的血浆UTN水平(中位数:6.5 ng/mL)显著高于年龄匹配的健康受试者(中位数:3.1 ng/mL)(p<0.001)。单因素分析显示,UTN与心率(r=-0.24)、透析治疗时长(r=-0.27)、去甲肾上腺素(r=-0.28)、神经肽Y(NPY)(r=-0.66)、脑钠肽(BNP)(r=-0.41)及心房钠尿肽(ANP)(r=-0.28)均呈负相关(所有p<0.008)。值得注意的是,在多元回归分析中,这些关联的强度与相应的未校正相关系数相似。

结论

UTN与神经激素因子之间的反向联系表明,在交感神经活动增强和BNP升高的情况下,UTN下调可能是一种旨在减轻心血管(CV)损伤的反调节反应,或者UTN本身就是一种保护因子。

相似文献

1
Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides.终末期肾病中的尾加压素II:交感神经功能与心钠素的负相关因素
J Nephrol. 2005 Nov-Dec;18(6):727-32.
2
Abnormal rhythmic oscillations of atrial natriuretic peptide and brain natriuretic peptide in chronic renal failure.慢性肾衰竭时心房利钠肽和脑利钠肽的异常节律性振荡
Clin Sci (Lond). 2006 Apr;110(4):491-501. doi: 10.1042/CS20050336.
3
Prognostic potential of brain natriuretic peptide (BNP) in predialysis chronic kidney disease patients.脑钠肽(BNP)在透析前慢性肾脏病患者中的预后潜力
Clin Sci (Lond). 2005 Jul;109(1):75-82. doi: 10.1042/CS20040351.
4
Effects of exercise testing on natriuretic peptide secretion in patients with atrial fibrillation.运动试验对心房颤动患者利钠肽分泌的影响。
Kardiol Pol. 2009 Mar;67(3):254-61.
5
Urotensin II and cardiomyopathy in end-stage renal disease.
Hypertension. 2008 Feb;51(2):326-33. doi: 10.1161/HYPERTENSIONAHA.107.101188. Epub 2007 Dec 17.
6
Daily dialyses decrease plasma levels of brain natriuretic peptide (BNP), a biomarker of left ventricular dysfunction.每日透析可降低血浆中脑钠肽(BNP)的水平,脑钠肽是左心室功能障碍的生物标志物。
Hemodial Int. 2006 Oct;10(4):394-8. doi: 10.1111/j.1542-4758.2006.00136.x.
7
Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease.尾加压素II是终末期肾病患者发生心血管事件的反向预测指标。
Kidney Int. 2006 Apr;69(7):1253-8. doi: 10.1038/sj.ki.5000114.
8
Natriuretic peptide response to dynamic exercise in patients with atrial fibrillation.心房颤动患者对动态运动的利钠肽反应。
Int J Cardiol. 2005 Oct 20;105(1):31-9. doi: 10.1016/j.ijcard.2004.10.046.
9
Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease.尾加压素 II 与终末期肾病中内皮激活和动脉粥样硬化的生物标志物
Am J Hypertens. 2006 May;19(5):505-10. doi: 10.1016/j.amjhyper.2005.10.019.
10
Plasma concentrations of natriuretic peptides in patients on hemodialysis.接受血液透析治疗患者的血浆利钠肽浓度
Res Commun Mol Pathol Pharmacol. 1996 Apr;92(1):19-30.

引用本文的文献

1
Plasma Urotensin II levels in children and adolescents with chronic kidney disease: a single-centre study.慢性肾脏病儿童及青少年的血浆尾加压素II水平:一项单中心研究
BMC Nephrol. 2017 Mar 31;18(1):113. doi: 10.1186/s12882-017-0530-9.
2
A closer look at the role of urotensin II in the metabolic syndrome.深入探讨尾加压素 II 在代谢综合征中的作用。
Front Endocrinol (Lausanne). 2012 Dec 28;3:165. doi: 10.3389/fendo.2012.00165. eCollection 2012.
3
Potential Clinical Implications of the Urotensin II Receptor Antagonists.尾加压素 II 受体拮抗剂的潜在临床意义。
Front Pharmacol. 2011 Jul 22;2:38. doi: 10.3389/fphar.2011.00038. eCollection 2011.
4
Urotensin II in cardiovascular regulation.心血管调节中的尾加压素II
Vasc Health Risk Manag. 2008;4(4):775-85. doi: 10.2147/vhrm.s1983.
5
Role of urotensin II and its receptor in health and disease.尾加压素II及其受体在健康与疾病中的作用。
J Anesth. 2007;21(3):378-89. doi: 10.1007/s00540-007-0524-z. Epub 2007 Aug 1.